Effets indésirables neurologiques des inhibiteurs de points de contrôle immunitaire

Key Points

• To explore the neurological adverse effects associated with immune checkpoint inhibitors and provide management strategies.
• Reviewed existing literature on immune-related adverse events (irAEs) related to neurological effects.
• Discussed evidence-based management strategies for prevention, diagnosis, and treatment of irAEs.
• Outlined decision criteria for resuming immune checkpoint inhibitor therapy post-irAE.
• Neurological complications from immune checkpoint inhibitors can arise from excessive immune responses.
• A comprehensive management approach can mitigate the impact of these neurological adverse effects.
• Clear criteria for treatment resumption can enhance patient safety following an irAE.